Opinion: Gilead is protecting its drug patent instead of protecting COVID-19 patients | BCRX Message Board Posts

BioCryst Pharmaceuticals Inc.

  BCRX website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left)  5-yrs @ $199 (only 31 left)  2-yrs @ $99 (only 29 left)

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  12265 of 12373  at  8/7/2020 2:20:35 PM  by

frnktofini


Opinion: Gilead is protecting its drug patent instead of protecting COVID-19 patients

 Gilead has great scientists and researchers and they should be amply rewarded for their success. Gilead should earn a fair profit for its work, but it should not get an unearned windfall, and it should not be able to lock up promising drugs merely because it is greedy. The public paid for the discovery of GS-441524 and remdesivir, and that intellectual property should be in the public domain.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 123
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...